UY32562A - Pirimidinas sustituidas por imidazol 724 - Google Patents
Pirimidinas sustituidas por imidazol 724Info
- Publication number
- UY32562A UY32562A UY0001032562A UY32562A UY32562A UY 32562 A UY32562 A UY 32562A UY 0001032562 A UY0001032562 A UY 0001032562A UY 32562 A UY32562 A UY 32562A UY 32562 A UY32562 A UY 32562A
- Authority
- UY
- Uruguay
- Prior art keywords
- compound
- hydrogen
- treatment
- imidazol
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
La presente invención se refiere a un nuevo compuesto de formula (I) en donde R1 es hidrogeno o floruro; R2 y R3 se selecciona independientemente de hidrogeno o metilo; o una sal farmacéuticamente aceptable del mismo, formulaciones farmacéuticas que contienen dicho compuesto, al uso de dicho compuesto activo en terapia, al uso para el tratamiento de afecciones asociadas con trastornos relacionados con la glucógeno sintasa quinasa 3, tales como enfermedad de Alzheimer, así como al método de tratamiento de dichos trastornos, que comprende administrar a un mamífero, incluyendo un ser humano que necesita dicho tratamiento, una cantidad terapéuticamente efectiva de dicho compuesto.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16940909P | 2009-04-15 | 2009-04-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY32562A true UY32562A (es) | 2010-11-30 |
Family
ID=42981442
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001032562A UY32562A (es) | 2009-04-15 | 2010-04-14 | Pirimidinas sustituidas por imidazol 724 |
Country Status (14)
Country | Link |
---|---|
US (2) | US20120077813A1 (es) |
EP (1) | EP2419425A4 (es) |
JP (1) | JP2012524063A (es) |
KR (1) | KR20120013951A (es) |
CN (1) | CN102459252A (es) |
AR (1) | AR076300A1 (es) |
AU (1) | AU2010237100A1 (es) |
BR (1) | BRPI1015014A2 (es) |
CA (1) | CA2761064A1 (es) |
MX (1) | MX2011010732A (es) |
RU (1) | RU2011140238A (es) |
TW (1) | TW201040169A (es) |
UY (1) | UY32562A (es) |
WO (1) | WO2010120237A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY29827A1 (es) * | 2005-10-03 | 2007-05-31 | Astrazeneca Ab | 2-amina-pirimidina-4-(2-metil-1-(tetrahidro-2h-piran-4-il)-1-imidazol-5-y1) sustituidas y sus derivados, composiciones farmacéuticas que las contienen, procesos para su preparación y aplicaciones |
CA2761064A1 (en) * | 2009-04-15 | 2010-10-21 | Astrazeneca Ab | Imidazole substituted pyrimidines useful in the treatment of glycogen synthase kinase 3 related disorders such as alzheimer's disease |
US8710092B2 (en) * | 2009-12-23 | 2014-04-29 | Map Pharmaceuticals, Inc. | Substituted indolo 4,3 FG quinolines useful for treating migraine |
WO2012050517A1 (en) * | 2010-10-14 | 2012-04-19 | Astrazeneca Ab | Imidazole substituted pyrimidine having a high gsk3 inhibiting potency as well as pan-kinase selectivity |
BR112013033339A2 (pt) | 2011-06-23 | 2016-08-16 | Map Pharmaceuticals Inc | análogos de fluorergolina |
SG11201403434YA (en) | 2011-12-19 | 2014-09-26 | Map Pharmaceuticals Inc | Novel iso-ergoline derivatives |
EP2793583A4 (en) | 2011-12-21 | 2015-08-12 | Map Pharmaceuticals Inc | NOVEL NEUROMODULATORY CONNECTIONS |
US9012640B2 (en) | 2012-06-22 | 2015-04-21 | Map Pharmaceuticals, Inc. | Cabergoline derivatives |
RU2014153672A (ru) * | 2012-06-22 | 2016-08-10 | Мап Фармасьютикалс, Инк. | Новые каберголиновые производные |
KR102413579B1 (ko) | 2015-10-06 | 2022-06-28 | 주식회사 에이치엘클레무브 | 운전자 편의 장치 및 그의 타겟 추정 방법 |
IL272988B (en) | 2017-09-08 | 2022-08-01 | Beigene Ltd | Imidazo-[1,5-a]pyrazine derivatives as pi3k-delta inhibitors |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE245641T1 (de) | 1998-02-17 | 2003-08-15 | Tularik Inc | Antivirale pyrimidinderivate |
GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
GB0021726D0 (en) | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
GB0022438D0 (en) | 2000-09-13 | 2000-11-01 | Novartis Ag | Organic Compounds |
MY130778A (en) | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
SE0100569D0 (sv) | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | New compounds |
ES2316546T3 (es) | 2001-02-20 | 2009-04-16 | Astrazeneca Ab | 2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3. |
CA2463822A1 (en) | 2001-11-01 | 2003-05-08 | Janssen Pharmaceutica N.V. | Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) |
GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
GB0205693D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
AU2003208479A1 (en) | 2002-03-09 | 2003-09-22 | Astrazeneca Ab | 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity |
WO2004005283A1 (en) | 2002-07-09 | 2004-01-15 | Vertex Pharmaceuticals Incorporated | Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities |
GB0226583D0 (en) | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
GB0229581D0 (en) | 2002-12-19 | 2003-01-22 | Cyclacel Ltd | Use |
EP1611125A1 (en) | 2003-02-07 | 2006-01-04 | Vertex Pharmaceuticals Incorporated | Heteroaryl substituted pyrolls useful as inhibitors of protein kinases |
WO2004083203A1 (en) | 2003-03-13 | 2004-09-30 | Vertex Pharmaceuticals Incorporated | Compositions useful as protein kinase inhibitors |
GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
WO2005012298A1 (en) | 2003-07-30 | 2005-02-10 | Cyclacel Limited | Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors |
TW200528101A (en) | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
BRPI0517426A (pt) | 2004-12-17 | 2008-10-07 | Astrazeneca Ab | composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito anti-proliferação celular, para produzir um efeito inibitório de cdk2, e para tratar uma doença em um animal de sangue quente |
GB0504753D0 (en) | 2005-03-08 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
CA2617170A1 (en) | 2005-07-30 | 2007-02-08 | Astrazeneca Ab | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders |
CN101312977B (zh) * | 2005-09-22 | 2012-06-13 | 布里斯托尔-迈尔斯.斯奎布公司 | 用作激酶调节剂的稠合杂环化合物 |
WO2007040436A1 (en) * | 2005-10-03 | 2007-04-12 | Astrazeneca Ab | Use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer’s disease |
UY29827A1 (es) | 2005-10-03 | 2007-05-31 | Astrazeneca Ab | 2-amina-pirimidina-4-(2-metil-1-(tetrahidro-2h-piran-4-il)-1-imidazol-5-y1) sustituidas y sus derivados, composiciones farmacéuticas que las contienen, procesos para su preparación y aplicaciones |
TW200811169A (en) | 2006-05-26 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
EP2029578A1 (en) | 2006-05-26 | 2009-03-04 | AstraZeneca AB | 2-carbocycloamino-4-imidaz0lylpyrimidines as agents for the inhbition of cell proliferation |
DE602007009535D1 (de) | 2006-06-21 | 2010-11-11 | Astrazeneca Ab | Chemische verbindungen |
TW200815417A (en) | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds II |
TW200815418A (en) | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds I |
EP2089017A2 (en) | 2006-11-02 | 2009-08-19 | Aestus Therapeutics, Inc. | Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways |
WO2009017453A1 (en) | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958 |
WO2009017455A1 (en) | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor |
WO2009017454A1 (en) | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960 |
CA2761064A1 (en) * | 2009-04-15 | 2010-10-21 | Astrazeneca Ab | Imidazole substituted pyrimidines useful in the treatment of glycogen synthase kinase 3 related disorders such as alzheimer's disease |
-
2010
- 2010-04-14 CA CA2761064A patent/CA2761064A1/en not_active Abandoned
- 2010-04-14 BR BRPI1015014A patent/BRPI1015014A2/pt not_active IP Right Cessation
- 2010-04-14 EP EP10764741A patent/EP2419425A4/en not_active Withdrawn
- 2010-04-14 UY UY0001032562A patent/UY32562A/es not_active Application Discontinuation
- 2010-04-14 JP JP2012505856A patent/JP2012524063A/ja active Pending
- 2010-04-14 MX MX2011010732A patent/MX2011010732A/es not_active Application Discontinuation
- 2010-04-14 RU RU2011140238/04A patent/RU2011140238A/ru not_active Application Discontinuation
- 2010-04-14 KR KR1020117024168A patent/KR20120013951A/ko not_active Application Discontinuation
- 2010-04-14 US US13/264,529 patent/US20120077813A1/en not_active Abandoned
- 2010-04-14 CN CN2010800265500A patent/CN102459252A/zh active Pending
- 2010-04-14 WO PCT/SE2010/050404 patent/WO2010120237A1/en active Application Filing
- 2010-04-14 AU AU2010237100A patent/AU2010237100A1/en not_active Abandoned
- 2010-04-14 US US12/759,869 patent/US8178529B2/en not_active Expired - Fee Related
- 2010-04-14 TW TW099111649A patent/TW201040169A/zh unknown
- 2010-04-14 AR ARP100101250A patent/AR076300A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20120013951A (ko) | 2012-02-15 |
CA2761064A1 (en) | 2010-10-21 |
TW201040169A (en) | 2010-11-16 |
BRPI1015014A2 (pt) | 2017-06-27 |
CN102459252A (zh) | 2012-05-16 |
RU2011140238A (ru) | 2013-05-20 |
EP2419425A4 (en) | 2012-08-29 |
MX2011010732A (es) | 2011-11-18 |
US8178529B2 (en) | 2012-05-15 |
AR076300A1 (es) | 2011-06-01 |
US20100267723A1 (en) | 2010-10-21 |
AU2010237100A1 (en) | 2011-10-27 |
EP2419425A1 (en) | 2012-02-22 |
US20120077813A1 (en) | 2012-03-29 |
WO2010120237A1 (en) | 2010-10-21 |
JP2012524063A (ja) | 2012-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY32562A (es) | Pirimidinas sustituidas por imidazol 724 | |
CO6270360A2 (es) | Antagonistas no basicos del receptor de la hormona concentradora de melanina 1 y procedimientos | |
CO6361928A2 (es) | Modulares de aril metil benzoquinazolinona alostericos positivos del receptor m1 | |
CO6470846A2 (es) | Derivados aminobut´ricos sustituidos como inhibidores de neprilisina | |
BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
CO6630133A2 (es) | Compuestos de pirazol -4-il heterociclil -carboxamida y métodos de uso | |
ECSP13013048A (es) | Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores | |
BR112013013950A2 (pt) | antagonista de lpa1 policíclico e usos dos mesmos | |
CU20110217A7 (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
BR112014009717A2 (pt) | "derivados de 2-(fenil ou pirid-3-il)aminopirimidina, seus usos, e composição farmacêutica" | |
MX2014002459A (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos. | |
UA104489C2 (uk) | Сполуки для лікування дисліпідемії та споріднених хвороб | |
EA201200686A1 (ru) | Новые терапевтические подходы для лечения болезни альцгеймера | |
MX356032B (es) | Compuestos indola y métodos para tratar el dolor visceral. | |
CR20130588A (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2 | |
CL2011002706A1 (es) | Compuestos derivados de 4-(1,3-oxazol-2-il)-1h-indazol; composicion farmaceutica que los comprende; y sus usos en el tratamiento de enfermedades tales como epoc, autoinmunes, asma, entre otras. | |
AR075729A1 (es) | Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes. | |
BR112012008518A2 (pt) | derivado heterocíclico, e, composição farmacêutica | |
MY166890A (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
DOP2005000039A (es) | Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
AR090601A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos | |
BR112014015482A2 (pt) | compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática | |
ECSP10010428A (es) | Derivados de indazol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20181127 |